Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

FDA Approval Author: Staff Editor Last Updated: Jul 7, 2016 - 5:36:25 PM



Watson's Generic Revatio® Receives FDA Approval

By Staff Editor
Nov 12, 2012 - 12:21:18 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - PARSIPPANY, N.J., Nov. 12, 2012 -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Sildenafil Tablets, 20 mg, the generic equivalent to Pfizer's Revatio(®). Watson intends to begin shipping the product in the near future. Revatio(®) is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening.

For the 12 months ending September 30, 2012, Revatio(®) tablets had total U.S. sales of approximately $339 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Watson is the world's third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Watson's global branded pharmaceutical business develops and markets products principally in Urology and Women's Health, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories. In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business. Watson has announced that it will adopt a new global name - Actavis - effective in 2013.

Revatio(®) is a registered trademark of Pfizer, Inc.

Web Site: http://www.watson.com

###

For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: [email protected] or 877-634-9180
HealthNewsDigest.com is syndicated worldwide, to thousands of journalists in all media, and health-related websites. www.HealthNewsDigest.com


Top of Page

HealthNewsDigest.com

FDA Approval
Latest Headlines


+ FDA Expands Approved Use of Stivarga to Treat Liver Cancer
+ FDA Approves First Treatment for Rare Form of Skin Cancer
+ Velano Vascular Receives Third FDA 510(k) Clearance for Innovative PIVO Needle-Free Blood Draw Technology
+ FDA Approves New Psoriasis Drug
+ Underarm Odor Banned with Newly Cleared FDA Treatment
+ AMA Applauds FDA for Approving New Naloxone Product to Prevent Fatal Opioid Overdoses
+ Vitamin D May Play Key Role in Preventing Macular Degeneration
+ Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg
+ FDA Approves VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older
+ FDA Approves Zydelig for Three Types of Blood Cancers



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions